Personne
Stephan Wullschleger
Cette personne n’est plus à l’EPFL
Publications associées (7)
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells
Douglas Hanahan, Mélanie Louise Tichet, Petra Catalina Schwalie, Stephan Wullschleger, Maria Karagianni
Expansion and differentiation of antigen-experienced PD-1(+)TCF-1(+) stem-like CD8(+) T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade(1-4). Hashimoto et al. have shown that, in chronic infections, administr ...
NATURE PORTFOLIO2022Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
Douglas Hanahan, Krisztian Homicsko, Mohammad Sadegh Saghafinia, Stephan Wullschleger, Iacovos Michael, Giovanni Ciriello
Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet tumors (IT) and invasive, metastasis-like primary (MLP) tumors. Until now, the origin of aggressive MLP tumors has been obscure. Herein, using multi-omics ap ...
AMER ASSOC CANCER RESEARCH2021Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers
Douglas Hanahan, Nadine Fournier, Mélanie Louise Tichet, Melody Swartz, Stephan Wullschleger, Gabriele Galliverti
Cancers induced by human papillomaviruses (HPV) should be responsive to immunotherapy by virtue of expressing the immunogenic oncoproteins E6/E7. However, advanced forms of cervical cancer, driven by HPV, are poorly responsive to immune response-enhancing ...
AMER ASSOC CANCER RESEARCH2020Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice
Douglas Hanahan, Mélanie Louise Tichet, Melody Swartz, Stephan Wullschleger, Gabriele Galliverti, Sylvie Hauert
Treatment of patients bearing human papillomavirus (HPV)-related cancers with synthetic long-peptide (SLP) therapeutic vaccines has shown promising results in clinical trials against premalignant lesions, whereas responses against later stage carcinomas ha ...
AMER ASSOC CANCER RESEARCH2018A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
Douglas Hanahan, Anguraj Sadanandam, Stephan Wullschleger, Ismaël Wafy
Seeking to assess the representative and instructive value of an engineered mouse model of pancreatic neuroendocrine tumors (PanNET) for its cognate human cancer, we profiled and compared mRNA and miRNA transcriptomes of tumors from both. Mouse PanNET tumo ...
Amer Assoc Cancer Research2015A colorectal cancer classification system that associates cellular phenotype and responses to therapy
Douglas Hanahan, Krisztian Homicsko, Anguraj Sadanandam, Stephan Wullschleger
Colorectal cancer (CRC) is a major cause of cancer mortality. Whereas some patients respond well to therapy, others do not, and thus more precise, individualized treatment strategies are needed. To that end, we analyzed gene expression profiles from 1,290 ...
Nature Publishing Group2013Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation
Anguraj Sadanandam, Stephan Wullschleger
BACKGROUND: Our earlier reports demonstrated that membrane-bound semaphorin 5A (SEMA5A) is expressed in aggressive pancreatic cancer cells and tumours, and promotes tumour growth and metastasis. In this study, we examine whether (1) pancreatic cancer cells ...
Nature Publishing Group2012